Effect of fingolimod (FTY720) on choroidal thickness in patients with multiple sclerosis

Abstract Objective Using spectral domain optical coherence tomography (SD-OCT), to compare the choroidal thickness in a healthy population (group 1), with newly diagnosed multiple sclerosis (MS) patients (group 2), with MS patients who underwent β-interferon monotherapy (group 3) and MS patients who...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders 2017-05, Vol.14, p.4-7
Main Authors: Kal, Ali, Oğuz Ulusoy, Mahmut, Horasanlı, Bahriye, Cezairlioğlu, Şefik, Kal, Öznur
Format: Article
Language:English
Subjects:
Adolescent
Adult
Case-Control Studies
Choroid - diagnostic imaging
Choroid - pathology
Choroidal thickness
Female
Fingolimod
Fingolimod Hydrochloride - therapeutic use
Humans
Immunologic Factors - therapeutic use
Immunosuppressive Agents - therapeutic use
Interferon-beta - therapeutic use
Male
Multiple sclerosis
Multiple Sclerosis - drug therapy
Neurology
Organ Size
Retrospective Studies
Tomography, Optical Coherence
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective Using spectral domain optical coherence tomography (SD-OCT), to compare the choroidal thickness in a healthy population (group 1), with newly diagnosed multiple sclerosis (MS) patients (group 2), with MS patients who underwent β-interferon monotherapy (group 3) and MS patients who underwent fingolimod therapy for 1 year (group 4) Methods Twenty-five control subjects (25 eyes), 24 newly diagnosed (24 eyes) MS patients, 22 MS patients who underwent fingolimod monotherapy for 1 year (22 eyes), and 24 MS patients who underwent β-interferon monotherapy for 1 year (24 eyes) were included in this study. The control group consisted of age- and gender-matched healthy individuals. The choroidal thickness measurements were performed using a high-speed and high-resolution SD-OCT device. The choroidal thickness measurements were compared using a One Way Anova and Post-Hoc Tukey test. Results Ninety-five eyes of 95 participants were included in this study. The mean age of the control group was 27.83±4.60, and it was 26.83±6.79, 27.87±6. 46 and 27.58±6.65 in the newly diagnosed MS group, fingolimod group and β-interferon group, respectively. In fingolimod group N-1000, N-1500 and T-1500 was significantly lower than control group. ( p =0.026, p =0.06 p =0.13) Conclusion Choroidal thickness values at N-1000, N-1500 and T-1500 levels in fingolimod group were found lower than in control but higher than in newly diagnosed MS group. This result can be explained with the therapeutic effect of the fingolimod on MS.
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2017.03.005